Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 2.

Table. 2.

Univariate and multivariate analysis of risk factor for overall survival rate (OSR)

Characteristics Univariate Multivariate


HR 95% CI p value HR 95% CI p value
Age ≥65 1.556 0.927-2.610 0.115
Male sex 0.918 0.537-1.568 0.785
BMI ≥25 1.355 0.752-2.441 0.370
High ASA class (3) 0.667 0.230-1.936 0.596
Left hepatectomy 1.660 0.903-3.048 0.126
No Caudate lobectomy 1.811 0.530-3.172 0.387
Pre-op biliary drainage 1.526 0.890-2.617 0.133
Pre-op Portal vein embolization 0.881 0.460-1.690 0741
Pre-op T.bil ≥3 1.607 0.923-2.797 0.097 1.194 0.660-2.162 0.558
Pre-op alb <3.5 0.776 0.464-1.298 0.361
Pre-op CA 19-9≥40 1.630 0.973-2.732 0.068 1.317 0.762-2.276 0.324
Tumor size ≥3 cm 1.607 0.959-2.695 0.089 1.275 0.738-2.203 0.384
Operation time >390 min 1.655 0.987-2.777 0.067 0.871 0.587-1.292 0.492
EBL ≥600 ml 2.024 1.202-3.407 0.009 1.688 1.133-2.514 0.010
Lymphovascular invasion 2.588 0.893-7.499 0.124
Perineural invasion 3.359 0.862-13.091 0.115
Portal vein resection 1.385 0.667-2.876 0.464
Portal vein true invasion 3.203 0.651-15.756 0.179
Positive resection margin 0.792 0.345-1.818 0.673
T3 versus T2/T1 2.887 1.331-6.261 0.007 2.403 1.540-3.747 0.001
Node metastasis 2.422 1.369-4.284 0.002 2.941 1.964-4.386 0.001
Poorly differentiation 2.666 1.329-4.974 0.002 1.890 1.260-2.836 0.002
No Adjuvant treatment 1.230 0.692-2.187 0.558

HR, hazard ratio; CI, confidence interval; BMI, body mass index; T. Bili, total bilirubin; CA19-9, cancer antigen 19-9; EBL, estimated blood loss

Ann Hepatobiliary Pancreat Surg 2021;25:221-9 https://doi.org/10.14701/ahbps.2021.25.2.221
© 2021 Ann Hepatobiliary Pancreat Surg